Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Tumour heterogeneity and the impact on patient care

Dr Nicholas McGranahan - The Francis Crick Institute, London, UK
Tumour heterogeneity and the impact on patient care ( Dr Nicholas McGranahan - The Francis Crick Institute, London, UK )
5 Oct 2016

Screening, surgical cure and new developments: How to avoid false positives in lung cancer screening

Dr Claudia Henschke - Mount Sinai Hospital, New York, USA
Screening, surgical cure and new developments: How to avoid false positives in lung cancer screening ( Dr Claudia Henschke - Mount Sinai Hospital, New York, USA )
5 Oct 2016

Omics, early detection and novel therapies: Q & A

Dr Murrell and Dr Pardo
Omics, early detection and novel therapies: Q & A ( Dr Murrell and Dr Pardo )
5 Oct 2016

Immunotherapy in SCLC

Prof Dean Fennell - University of Leicester, Leicester, UK
Immunotherapy in SCLC ( Prof Dean Fennell - University of Leicester, Leicester, UK )
5 Oct 2016

Omics, early detection and novel therapies: Metabolomics

Dr Olivier Pardo - Imperial College London, London, UK
Omics, early detection and novel therapies: Metabolomics ( Dr Olivier Pardo - Imperial College London, London, UK )
5 Oct 2016

Omics, early detection and novel therapies: Epigenetic studies

Dr Adele Murrell - University of Bath, Bath, UK
Omics, early detection and novel therapies: Epigenetic studies ( Dr Adele Murrell - University of Bath, Bath, UK )
5 Oct 2016

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK
We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )
5 Oct 2016

Using PDL1 and other biomarkers in patient selection for immunology: Q & A

Dr O'Brien and Prof McVie
Using PDL1 and other biomarkers in patient selection for immunology: Q & A ( Dr O'Brien and Prof McVie )
5 Oct 2016

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Prof Gordon McVie - King's College London, London, UK
We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Prof Gordon McVie - King's College London, London, UK )
5 Oct 2016

Imaging and novel PET tracers: Q & A

Dr Giulia Veronesi and Prof Tony Ng
Imaging and novel PET tracers: Q & A ( Dr Giulia Veronesi and Prof Tony Ng )
5 Oct 2016

Current standards of care in advanced NSCLC

Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada
Current standards of care in advanced NSCLC ( Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada )
5 Oct 2016

Imaging and novel PET tracers: State of the art

Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy
Imaging and novel PET tracers: State of the art ( Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy )
5 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation